Does Keflex (cephalexin) cover gram-negative rods?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Keflex (Cephalexin) Coverage of Gram-Negative Rods

Keflex has limited and unreliable activity against gram-negative rods and should not be relied upon as primary therapy when gram-negative coverage is needed. 1

Spectrum Against Gram-Negative Organisms

Organisms with Documented Activity

According to the FDA label, cephalexin demonstrates activity against only a narrow subset of gram-negative bacteria: 1

  • Escherichia coli - susceptible strains
  • Klebsiella pneumoniae - susceptible strains
  • Proteus mirabilis - susceptible strains
  • Haemophilus influenzae - susceptible strains
  • Moraxella catarrhalis - susceptible strains

Critical Gaps in Coverage

Cephalexin has NO activity against: 1

  • Most strains of Enterobacter species
  • Morganella morganii
  • Proteus vulgaris
  • Pseudomonas species (completely inactive)
  • Acinetobacter calcoaceticus

Clinical Guideline Recommendations

When Cephalexin Is Appropriate

IDSA guidelines list cephalexin only for mild diabetic foot infections where the expected pathogens are primarily gram-positive (Staphylococcus aureus and Streptococcus species), with the caveat that it requires QID dosing and is inexpensive. 2

When Cephalexin Is Inadequate

For infections requiring reliable gram-negative coverage, IDSA guidelines explicitly recommend alternative agents: 2

  • Moderate-to-severe infections with Enterobacteriaceae: Use levofloxacin, ceftriaxone, ertapenem, or ampicillin-sulbactam 2
  • Animal bite wounds: First-generation cephalosporins (including cephalexin) "miss P. multocida and anaerobes" - amoxicillin-clavulanate is preferred 2
  • Human bite wounds: Cephalexin "misses E. corrodens and gram-negative anaerobes" 2

Comparative Potency Data

Historical research demonstrates cephalexin is the weakest among first-generation cephalosporins against gram-negative rods: 3

  • Against E. coli, the relative potency in decreasing order is: cefazolin > cephaloridine > cephalexin > cephalothin 3
  • Only 49.1% of Staphylococcus aureus strains were suppressed by cephalexin at ≤3.13 mcg/mL, compared to >90% for other first-generation agents 3

Clinical Pitfalls to Avoid

Never use cephalexin when: 4, 5

  • Gram-negative rods are the suspected or confirmed pathogen requiring definitive therapy
  • Polymicrobial infections involving gram-negative organisms are present
  • Pseudomonas or other non-fermenting gram-negative rods are possible
  • Hospital-acquired infections are suspected (high risk of resistant gram-negatives) 5

If gram-negative coverage is uncertain but needed, choose agents with broader and more reliable activity: 2

  • Oral options: Levofloxacin, amoxicillin-clavulanate, or moxifloxacin
  • Parenteral options: Ceftriaxone, ertapenem, or piperacillin-tazobactam

Bottom Line for Clinical Practice

While the FDA label lists some gram-negative organisms in cephalexin's spectrum, this does not translate to reliable clinical coverage. 1 The drug is positioned by major guidelines exclusively for gram-positive infections or very mild community-acquired infections where gram-positive organisms predominate. 2 When gram-negative rods are documented or suspected, select an agent with proven broader gram-negative activity rather than risking treatment failure with cephalexin.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Evaluation of antibacterial activities of cephalosporin antibiotics: cefazolin, cephaloridine, cephalothin, and cephalexin.

Zhonghua Minguo wei sheng wu xue za zhi = Chinese journal of microbiology, 1975

Guideline

Clindamycin Spectrum of Activity and Clinical Implications

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment of Moderate Gram-Negative Rods in Sputum

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.